|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression multiple interactions |
EXP |
Rosmarinic Acid results in decreased expression of ACTA2 protein Rosmarinic Acid inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] |
CTD |
PMID:28789951 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adam17 |
ADAM metallopeptidase domain 17 |
decreases expression multiple interactions |
ISO |
Rosmarinic Acid results in decreased expression of ADAM17 protein [Rosmarinic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ADAM17 protein]] which affects the localization of PROCR protein; [Rosmarinic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ADAM17 protein]] which results in decreased cleavage of and results in decreased secretion of PROCR protein; [Rosmarinic Acid results in decreased expression of ADAM17 protein] inhibits the reaction [IL1B protein affects the localization of PROCR protein]; [Rosmarinic Acid results in decreased expression of ADAM17 protein] inhibits the reaction [IL1B protein results in increased cleavage of and results in increased secretion of PROCR protein]; [Rosmarinic Acid results in decreased expression of ADAM17 protein] inhibits the reaction [TNF protein affects the localization of PROCR protein]; [Rosmarinic Acid results in decreased expression of ADAM17 protein] inhibits the reaction [TNF protein results in increased cleavage of and results in increased secretion of PROCR protein]; Rosmarinic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ADAM17 protein] |
CTD |
PMID:23774263 |
|
NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
ISO |
Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein] |
CTD |
PMID:33476690 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
multiple interactions |
ISO |
Rosmarinic Acid inhibits the reaction [Cadmium affects the localization of AIFM1 protein]; Rosmarinic Acid inhibits the reaction [Cisplatin affects the localization of AIFM1 protein] |
CTD |
PMID:21526214 PMID:23548128 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
Rosmarinic Acid inhibits the reaction [Cisplatin results in increased expression of BAX protein] |
CTD |
PMID:21526214 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
Rosmarinic Acid inhibits the reaction [Cisplatin results in decreased expression of BCL2 protein] |
CTD |
PMID:21526214 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
Rosmarinic Acid inhibits the reaction [Cisplatin results in increased activity of CASP1 protein] |
CTD |
PMID:21526214 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression |
ISO EXP |
Rosmarinic Acid inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased activity of CASP3 protein]; Rosmarinic Acid inhibits the reaction [Cadmium results in increased activity of CASP3 protein]; Rosmarinic Acid inhibits the reaction [Cisplatin results in increased activity of CASP3 protein] Rosmarinic Acid inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein] Rosmarinic Acid results in increased expression of CASP3 mRNA |
CTD |
PMID:20966113 PMID:21526214 PMID:23548128 PMID:28815802 PMID:36863647 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases expression increases activity |
ISO |
Rosmarinic Acid results in increased expression of CASP8 mRNA Rosmarinic Acid results in increased activity of CASP8 protein |
CTD |
PMID:36863647 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
Rosmarinic Acid inhibits the reaction [Cisplatin results in increased activity of CASP9 protein] |
CTD |
PMID:21526214 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
increases activity increases expression multiple interactions |
ISO |
Rosmarinic Acid results in increased activity of CAT protein Rosmarinic Acid results in increased expression of CAT mRNA Rosmarinic Acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased activity of CAT protein]; Rosmarinic Acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of CAT mRNA] |
CTD |
PMID:31610155 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions decreases expression |
EXP |
Rosmarinic Acid inhibits the reaction [TGFB1 protein results in increased expression of CCN2 protein] Rosmarinic Acid results in decreased expression of CCN2 mRNA |
CTD |
PMID:28789951 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
EXP |
Rosmarinic Acid inhibits the reaction [TGFB1 protein results in increased expression of CCND1 protein] |
CTD |
PMID:28789951 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cd68 |
Cd68 molecule |
decreases expression |
EXP |
Rosmarinic Acid results in decreased expression of CD68 protein |
CTD |
PMID:28789951 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein] |
CTD |
PMID:33476690 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression multiple interactions |
EXP ISO |
Rosmarinic Acid results in decreased expression of COL1A1 mRNA Rosmarinic Acid inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:27235791 PMID:28789951 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions decreases expression |
EXP |
Rosmarinic Acid inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA] Rosmarinic Acid results in decreased expression of COL3A1 mRNA |
CTD |
PMID:28789951 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Crp |
C-reactive protein |
affects expression multiple interactions |
EXP |
Rosmarinic Acid affects the expression of CRP protein 2-chloro-5-nitrobenzanilide inhibits the reaction [Rosmarinic Acid affects the expression of CRP protein]; T 0070907 inhibits the reaction [Rosmarinic Acid affects the expression of CRP protein] |
CTD |
PMID:28744220 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
decreases expression multiple interactions |
ISO |
Rosmarinic Acid results in decreased expression of CXCL1 mRNA Rosmarinic Acid inhibits the reaction [Particulate Matter results in increased expression of CXCL1 protein]; Rosmarinic Acid inhibits the reaction [Vehicle Emissions results in increased expression of CXCL1 protein] |
CTD |
PMID:12684091 PMID:26804033 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Des |
desmin |
multiple interactions |
EXP |
Rosmarinic Acid inhibits the reaction [TGFB1 protein results in increased expression of DES protein] |
CTD |
PMID:28789951 |
|
NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
decreases expression |
ISO |
Rosmarinic Acid results in decreased expression of DNMT1 protein |
CTD |
PMID:21078381 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions |
ISO |
Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression |
ISO |
Rosmarinic Acid results in decreased expression of FN1 mRNA |
CTD |
PMID:26804033 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression |
EXP |
Rosmarinic Acid results in decreased expression of FOS protein |
CTD |
PMID:28789951 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
decreases activity |
EXP |
Rosmarinic Acid results in decreased activity of GPT protein |
CTD |
PMID:25455894 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases expression multiple interactions |
ISO |
Rosmarinic Acid results in increased expression of GPX1 mRNA Rosmarinic Acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of GPX1 mRNA] |
CTD |
PMID:31610155 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsto1 |
glutathione S-transferase omega 1 |
multiple interactions increases expression |
ISO |
Rosmarinic Acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of GSTO1 mRNA] Rosmarinic Acid results in increased expression of GSTO1 mRNA |
CTD |
PMID:31610155 |
|
NCBI chr 1:246,721,089...246,731,228
Ensembl chr 1:246,721,221...246,731,468
|
|
G |
Hmgb1 |
high mobility group box 1 |
decreases expression |
EXP |
Rosmarinic Acid results in decreased expression of HMGB1 protein |
CTD |
PMID:28789951 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO |
Rosmarinic Acid results in increased expression of HMOX1 mRNA Rosmarinic Acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of HMOX1 mRNA] |
CTD |
PMID:31610155 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
ISO |
Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression |
ISO EXP |
[Rosmarinic Acid results in decreased expression of ADAM17 protein] inhibits the reaction [IL1B protein affects the localization of PROCR protein]; [Rosmarinic Acid results in decreased expression of ADAM17 protein] inhibits the reaction [IL1B protein results in increased cleavage of and results in increased secretion of PROCR protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA] Rosmarinic Acid inhibits the reaction [Cadmium results in increased expression of IL1B protein]; Rosmarinic Acid inhibits the reaction [Particulate Matter results in increased expression of IL1B protein]; Rosmarinic Acid inhibits the reaction [Vehicle Emissions results in increased expression of IL1B protein] Rosmarinic Acid results in decreased expression of IL1B mRNA; Rosmarinic Acid results in decreased expression of IL1B protein |
CTD |
PMID:12684091 PMID:23548128 PMID:23774263 PMID:25455894 PMID:28789951 PMID:33476690 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions affects expression increases expression decreases expression |
ISO EXP |
Rosmarinic Acid inhibits the reaction [Cadmium results in increased expression of IL6 protein] 2-chloro-5-nitrobenzanilide inhibits the reaction [Rosmarinic Acid affects the expression of IL6 protein]; T 0070907 inhibits the reaction [Rosmarinic Acid affects the expression of IL6 protein] Rosmarinic Acid results in increased expression of IL6 mRNA Rosmarinic Acid results in decreased expression of IL6 mRNA Rosmarinic Acid results in decreased expression of IL6 protein |
CTD |
PMID:23548128 PMID:26804033 PMID:28744220 PMID:28789951 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
[Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
decreases phosphorylation |
EXP |
Rosmarinic Acid results in decreased phosphorylation of JUN protein |
CTD |
PMID:28789951 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcnu1 |
potassium calcium-activated channel subfamily U member 1 |
decreases activity |
ISO |
Rosmarinic Acid results in decreased activity of KCNU1 protein |
CTD |
PMID:30009954 |
|
NCBI chr16:66,141,696...66,229,493
Ensembl chr16:66,141,976...66,229,465
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
decreases expression multiple interactions |
ISO |
Rosmarinic Acid results in decreased expression of KEAP1 protein Rosmarinic Acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of KEAP1 protein] |
CTD |
PMID:31610155 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Maoa |
monoamine oxidase A |
decreases activity |
ISO |
Rosmarinic Acid results in decreased activity of MAOA protein |
CTD |
PMID:27270453 |
|
NCBI chr X:6,032,172...6,098,308
Ensembl chr X:6,030,795...6,099,593
|
|
G |
Maob |
monoamine oxidase B |
decreases activity |
ISO |
Rosmarinic Acid results in decreased activity of MAOB protein |
CTD |
PMID:27270453 |
|
NCBI chr X:5,907,327...6,010,996
Ensembl chr X:5,907,266...6,011,003
|
|
G |
Map3k7 |
mitogen activated protein kinase kinase kinase 7 |
decreases phosphorylation |
EXP |
Rosmarinic Acid results in decreased phosphorylation of MAP3K7 protein |
CTD |
PMID:28789951 |
|
NCBI chr 5:46,356,973...46,415,597
Ensembl chr 5:46,357,931...46,415,597
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases phosphorylation |
EXP |
Rosmarinic Acid results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:28789951 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases phosphorylation |
EXP |
Rosmarinic Acid results in decreased phosphorylation of MAPK3 protein |
CTD |
PMID:28789951 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
decreases phosphorylation |
EXP |
Rosmarinic Acid results in decreased phosphorylation of MAPK8 protein |
CTD |
PMID:28789951 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
decreases phosphorylation |
EXP |
Rosmarinic Acid results in decreased phosphorylation of MAPK9 protein |
CTD |
PMID:28789951 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression |
EXP |
Rosmarinic Acid results in decreased expression of MMP2 mRNA; Rosmarinic Acid results in decreased expression of MMP2 protein |
CTD |
PMID:28789951 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression |
EXP |
Rosmarinic Acid results in decreased expression of MMP9 mRNA; Rosmarinic Acid results in decreased expression of MMP9 protein |
CTD |
PMID:28789951 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
decreases expression |
EXP |
Rosmarinic Acid results in decreased expression of MPO protein |
CTD |
PMID:28789951 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
decreases expression |
EXP |
Rosmarinic Acid results in decreased expression of MYD88 protein |
CTD |
PMID:28789951 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression multiple interactions |
ISO |
Rosmarinic Acid results in increased expression of NFE2L2 mRNA; Rosmarinic Acid results in increased expression of NFE2L2 protein [lead acetate results in increased abundance of Lead] inhibits the reaction [Rosmarinic Acid results in increased expression of NFE2L2 protein]; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; Rosmarinic Acid affects the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of NFE2L2 mRNA] |
CTD |
PMID:31610155 PMID:33476690 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA Rosmarinic Acid inhibits the reaction [Cisplatin results in increased degradation of NFKBIA protein] |
CTD |
PMID:21526214 PMID:33476690 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
decreases expression |
ISO |
Rosmarinic Acid results in decreased expression of NLRP3 mRNA |
CTD |
PMID:36863647 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases expression |
EXP |
Rosmarinic Acid inhibits the reaction [Doxorubicin results in increased expression of NOS2 protein] Rosmarinic Acid results in decreased expression of NOS2 protein |
CTD |
PMID:25455894 PMID:28815802 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
decreases expression |
EXP |
Rosmarinic Acid results in decreased expression of NOS3 protein |
CTD |
PMID:25455894 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases expression |
ISO |
Rosmarinic Acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of NQO1 mRNA] Rosmarinic Acid results in increased expression of NQO1 mRNA |
CTD |
PMID:31610155 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
increases expression |
EXP |
Rosmarinic Acid results in increased expression of OGG1 mRNA |
CTD |
PMID:18996367 |
|
NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
|
|
G |
Parg |
poly (ADP-ribose) glycohydrolase |
decreases activity |
ISO |
Rosmarinic Acid results in decreased activity of PARG protein |
CTD |
PMID:19840838 |
|
NCBI chr16:7,436,429...7,544,276
Ensembl chr16:7,436,476...7,544,273
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
multiple interactions |
ISO |
Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects expression multiple interactions |
EXP ISO |
Rosmarinic Acid affects the expression of PPARG mRNA; Rosmarinic Acid affects the expression of PPARG protein 2-chloro-5-nitrobenzanilide inhibits the reaction [Rosmarinic Acid affects the expression of PPARG mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Rosmarinic Acid affects the expression of PPARG protein]; T 0070907 inhibits the reaction [Rosmarinic Acid affects the expression of PPARG mRNA]; T 0070907 inhibits the reaction [Rosmarinic Acid affects the expression of PPARG protein] Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein] |
CTD |
PMID:28744220 PMID:33476690 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Procr |
protein C receptor |
affects localization multiple interactions |
ISO |
Rosmarinic Acid affects the localization of PROCR protein [Rosmarinic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ADAM17 protein]] which affects the localization of PROCR protein; [Rosmarinic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ADAM17 protein]] which results in decreased cleavage of and results in decreased secretion of PROCR protein; [Rosmarinic Acid results in decreased expression of ADAM17 protein] inhibits the reaction [IL1B protein affects the localization of PROCR protein]; [Rosmarinic Acid results in decreased expression of ADAM17 protein] inhibits the reaction [IL1B protein results in increased cleavage of and results in increased secretion of PROCR protein]; [Rosmarinic Acid results in decreased expression of ADAM17 protein] inhibits the reaction [TNF protein affects the localization of PROCR protein]; [Rosmarinic Acid results in decreased expression of ADAM17 protein] inhibits the reaction [TNF protein results in increased cleavage of and results in increased secretion of PROCR protein]; Rosmarinic Acid inhibits the reaction [Tetradecanoylphorbol Acetate affects the localization of PROCR protein]; Rosmarinic Acid results in decreased cleavage of and results in decreased secretion of PROCR protein |
CTD |
PMID:23774263 |
|
NCBI chr 3:144,254,596...144,258,863
Ensembl chr 3:144,254,380...144,258,903
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions affects localization decreases phosphorylation affects expression |
EXP ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [Rosmarinic Acid affects the expression of RELA mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Rosmarinic Acid affects the expression of RELA protein]; T 0070907 inhibits the reaction [Rosmarinic Acid affects the expression of RELA mRNA]; T 0070907 inhibits the reaction [Rosmarinic Acid affects the expression of RELA protein] Rosmarinic Acid affects the localization of RELA protein Rosmarinic Acid results in decreased phosphorylation of RELA protein Rosmarinic Acid affects the expression of RELA mRNA; Rosmarinic Acid affects the expression of RELA protein Rosmarinic Acid inhibits the reaction [Cisplatin affects the localization of RELA protein] |
CTD |
PMID:21526214 PMID:25455894 PMID:28744220 PMID:28789951 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Serpine1 |
serpin family E member 1 |
decreases expression |
ISO |
Rosmarinic Acid results in decreased expression of SERPINE1 mRNA |
CTD |
PMID:26804033 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions increases expression |
ISO |
Rosmarinic Acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of SOD1 mRNA] Rosmarinic Acid results in increased expression of SOD1 mRNA |
CTD |
PMID:31610155 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases expression |
ISO |
Rosmarinic Acid inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of SOD2 mRNA] Rosmarinic Acid results in increased expression of SOD2 mRNA |
CTD |
PMID:31610155 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Tf |
transferrin |
multiple interactions |
ISO |
[Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of NFE2L2 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA; [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of NFKBIA mRNA; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA mRNA]; Rosmarinic Acid affects the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARGC1A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL10 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of IL17A mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ACACA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of ADIPOQ protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of CEBPA protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FABP4 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of FASN mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of IL1B mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARA mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARD mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of PPARG protein]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of SREBF1 mRNA]; Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases expression multiple interactions |
EXP ISO |
Rosmarinic Acid results in decreased expression of TGFB1 protein Rosmarinic Acid inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; Rosmarinic Acid inhibits the reaction [TGFB1 protein results in increased expression of CCN2 protein]; Rosmarinic Acid inhibits the reaction [TGFB1 protein results in increased expression of CCND1 protein]; Rosmarinic Acid inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; Rosmarinic Acid inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA]; Rosmarinic Acid inhibits the reaction [TGFB1 protein results in increased expression of DES protein]; Rosmarinic Acid inhibits the reaction [TGFB1 protein results in increased expression of VIM protein] [Rosmarinic Acid co-treated with Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in decreased expression of TGFB1 mRNA |
CTD |
PMID:28789951 PMID:33476690 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tlr4 |
toll-like receptor 4 |
decreases expression |
EXP |
Rosmarinic Acid results in decreased expression of TLR4 protein |
CTD |
PMID:28789951 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
affects expression multiple interactions decreases expression |
EXP ISO |
Rosmarinic Acid affects the expression of TNF protein [Rosmarinic Acid results in decreased expression of ADAM17 protein] inhibits the reaction [TNF protein affects the localization of PROCR protein]; [Rosmarinic Acid results in decreased expression of ADAM17 protein] inhibits the reaction [TNF protein results in increased cleavage of and results in increased secretion of PROCR protein] 2-chloro-5-nitrobenzanilide inhibits the reaction [Rosmarinic Acid affects the expression of TNF protein]; Rosmarinic Acid inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; T 0070907 inhibits the reaction [Rosmarinic Acid affects the expression of TNF protein] Rosmarinic Acid results in decreased expression of TNF mRNA; Rosmarinic Acid results in decreased expression of TNF protein |
CTD |
PMID:23774263 PMID:25455894 PMID:28744220 PMID:28789951 PMID:28815802 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Ucp1 |
uncoupling protein 1 |
multiple interactions |
ISO |
Rosmarinic Acid inhibits the reaction [[Rosiglitazone co-treated with TF protein co-treated with INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Hydrocortisone co-treated with Triiodothyronine] results in increased expression of UCP1 mRNA] |
CTD |
PMID:33476690 |
|
NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852
|
|
G |
Vim |
vimentin |
multiple interactions |
EXP |
Rosmarinic Acid inhibits the reaction [TGFB1 protein results in increased expression of VIM protein] |
CTD |
PMID:28789951 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|